We partner with the media to inform the public of the global human crisis.
Updates on the Department of Justice Action
Get updates and information on Indivior’s ongoing response to the recent action by the U.S. Department of Justice and learn about the company’s unwavering commitment to patients, doctors, and communities fighting opioid addiction.
See more >
April 9, 2019Company Believes U.S. Justice Department Is Fundamentally Wrong, Will Contest Charges Vigorously...
April 8, 2019Indivior Announces New Study Data in Patients with Moderate to Severe Opioid Use Disorder (OUD) at the 50th ASAM Annual Conference ...
April 5, 2019Indivior’s RECOVER™ Study Finds Three-quarters of Patients with Moderate to Severe Opioid Use Disorder Who Received 12 monthly Injections of SUBLOCADE™ (Buprenorphine Extended-Release) Injection were Abstinent from Illicit Opioids One Year Later...
March 14, 2019Annual Report & Accounts 2018 and Annual General Meeting 2019...
March 7, 2019The Journal of Addiction Medicine Publishes Patient-centered Outcomes from the Phase 3 Study of SUBLOCADE™ (Buprenorphine Extended-Release) Injection in Patients with Moderate to Severe Opioid Use Disorder (OUD) ...
Global Media Contacts
EMEA, Australasia and China Financial Disclosure Reporting
Disclosure Of Payments, Donations & Joint Working
The Online Press Kit is designed to help media research our company for background information or follow-up stories. Please visit the links below to learn more.
About Indivior PLC – An overview of Indivior, including our worldwide locations and key products
Board of Directors – Biographies of Indivior’s Board
The Indivior PLC Pipeline – Information about the Indivior R&D efforts and progress of medicines in the pipeline